Expression of costimulatory molecules in human leukemias

Leukemia

Volumn 10, Issue 7, 1996, Pages 1168-1176

  Hirano, N ^a   Takahashi, T ^a,a   Ohtake, S ^b   Hirashima, K ^c   Emi, N ^d   Saito, K ^e   Hirano, M ^f   Shinohara, K ^g   Takeuchi, M ^h   Taketazu, F ⁱ   Tsunoda, S ^j   Ogura, M ^k   Omine, M ^l   Saito, T ^m   Yazaki, Y ^a   Ueda, R ^k   Hirai, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b KANAZAWA UNIVERSITY   (Japan)

^c SAITAMA MEDICAL UNIVERSITY   (Japan)

^d NAGOYA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^e DOKKYO MEDICAL UNIVERSITY   (Japan)

^f FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g Yamaguchi Prefectual Central Hospital   (Japan)

^h Natl Sanit Minami Okayama Hospital   (Japan)

ⁱ JICHI MEDICAL UNIVERSITY   (Japan)

^j TOCHIGI CANCER CENTER   (Japan)

^k AICHI CANCER CENTER HOSPITAL   (Japan)

^l SHOWA UNIVERSITY FUJIGAOKA HOSPITAL   (Japan)

^m TEIKYO UNIVERSITY   (Japan)

more..

Author keywords

B 2; B7 1; Costimulatory molecules; ICAM 1; Leukemia

Indexed keywords

B7 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER IMMUNOTHERAPY; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL;

EID: 9344269897     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Ostrand-Rosenberg S, Thakur A, Clements VK. Rejection of mouse sarcoma cells after transfection of MHC class II genes. J Immunol 1990; 144: 4068-4071.
2. Ostrand-Rosenberg S, Roby CA, Clements VK. Abrogation of tumorigenicity by MHC class II antigen expression requires the cytoplasmic domain of the class II molecule. J Immunol 1991; 147: 2419-2422.
3. Wallich R, Bulbuc N, Hammerling GJ, Katzav S, Segal S, Feldman M. Abrogation of metastatic properties of tumour cells by de novo expression of H-2K antigens following H-2 gene transfection. Nature 1985; 315: 301-305.
4. Boon T, DePlaen E, Lurquin C, van den Eynde B, van der Bruggen P, Traversari C, Amar-Costesec A, Van Pel A. Identification of tumour rejection antigens recognized by T lyphocytes. Cancer Surv 1992; 13: 23-37.
5. van der Bruggen P, Traversari C, Chomez P, Lurquin C, DePlaen E, Van den Eynde B, Knuth A, Boon T. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-1647.
6. Restifo NP, Esquivel F, Asher AL, Stotter H, Barth RJ, Bennink JR, Mule JJ, Yewdell JW, Rosenberg SA. Defective presentation of endogenous antigens by a murine sarcoma. Implications for the failure of an anti-tumor immune response. J Immunol 1991; 147: 1453-1459.
7. Restifo NP, Esquivel F, Kawakami Y, Yewdell JW, Mule JJ, Rosenberg SA, Bennink JR. Identification of human cancers deficient in antigen processing. J Exp Med 1993; 177: 265-272.
8. Alexander MA, Bennicelli J, Guerry D. Defective antigen presentation by human melanoma cell lines cultured trom advanced, but not biologically early, disease. J Immunol 1989; 142: 4070-4078.
9. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94-97.
10. Townsend SE, Allison JP. Tumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
11. Chen L, Ashe S, Brady WA, Hellström I, Hellström KE, Ledbetter JA, McGowan P, Linsley PS. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
12. Dranoff G, Jaffee E, Lazenby A, Golumbek P, Levitsky H, Brose K, Jackson V, Hamada H, Pardoll D, Mulligan RC. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
13. Gansbacher B, Zier K, Daniels B, Cronin K, Bannerji R, Gilboa E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
14. Golumbek PT, Lazenby AJ, Levitsky HI, Jaffee LM, Karasuyama H, Baker M, Pardoll DM. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716.
15. Fearon ER, Pardoll DM, Itaya T, Golumbek P, Levitsky HI, Simons JW, Karasuyama H, Vogelstein B, Frost P. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 1990; 60: 397-403.
16. Colombo MP, Ferrari G, Stoppacciaro A, Parenza M, Rodolfo M, Mavilio F, Parmiani G. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo. J Exp Med 1991; 173: 889-897.
17. Yang G, Hellstrom KE, Hellstrom I, Chen L. Antitumor immunity elicited by tumor cells transfected with B7-2, a second ligand for CD28/CTLA-4 costimulatory molecules. J Immunol 1995; 154: 2794-2800.
18. Chen L, McGowan P, Ashe S, Johnston J, Li Y, Hellström I, Hellström KE. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med 1994; 179: 523-532.
19. Cavallo F, Martin FA, Bellone M, Heltai S, Gatti E, Tornaghi P, Freschi M, Forni G, Dellabona P, Casorati G. Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response. Eur J Immunol 1995; 25: 1154-1162.
20. Matulonis UA, Dosiou C, Lamont C, Freeman GJ, Mauch P, Nadler LM, Griffin JD. Role of B7-1 in mediating an immune response to myeloid leukemia cells. Blood 1995; 85: 2507-2515.
21. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol 1991; 78: 325-329.
22. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol 1981; 47: 553-561.
23. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C. Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol 1976; 33: 451-458.
24. Foon KA, Gale RP, Todd RF. Immunologic approaches to the classification of lymphomas and lymphoid leukemias. Cancer Treat Res 1988; 38: 1-30.
25. Houlihan JM, Biro PA, Fergar-Payne A, Simpson KL, Holmes CH. Evidence for the expression of non-HLA-A,-B,-C class I genes in the human fetal liver. J Immunol 1992; 149: 668-675.
26. Le Bouteiller P. HLA class I chromosomal region, genes, and products: facts and questions. Crit Rev Immunol 1994; 14: 89-129.
27. Bensussan A, Mansur IG, Mallet V, Rodriguez AM, Girr M, Weiss EH, Brem C, Boumsell L, Gluckman E, Dausset J, Carosella E, Le Bouteiller P. Detection of membrane-bound HLA-G translated products with a specific monoclonal antibody. Proc Natl Acad Sci USA 1995; 92: 10292-10296.
28. Maio M, Pinto A, Carbone A, Zagonel V, Gloghini A, Marotta G, Cirillo D, Colombatti A, Ferrara F, DelVecchio L. Differential expression of CD54/intercellular adhesion molecule-1 in myeloid leukemias and in lymphoproliferative disorders. Blood 1990; 76: 783-790.
29. Orgad S, Yunis EJ, Zaizov R, Ramot B, Altshuler R, Gazit E. Expression of HLA-DR alloantigens on acute lymphoblastic leukemia lymphoblasts. Hum Immunol 1984; 9: 67-74.
30. Merle-Beral H, Nguyen Cong Duc L, Leblond V, Boucheix C, Michel A, Chastang C, Debre P. Diagnostic and prognostic significance of myelompnpcytic cell surface antigens in acute myeloid leukemia. Br J Haematol 1989; 7: 323-330.
31. Ohta M, Furukawa Y, Ide C, Akiyama N, Utakoji T, Miura Y, Saito M. Establishment and characterization of four human monocytoid leukemia cell lines (JOSK-1, -S, -M and -K) with capabilities of monocyte-macrophage lineage differentiation and constitutive production of interleukin 1. Cancer Res 1986; 46: 3067-3074.
32. Thompson CB. Distinct roles for the costimulatory ligands B7-1 and B7-2 in T helper cell differentiation? Cell 1995; 81: 979-982.
33. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 1987; 139: 3260-3267.
34. Freeman GJ, Freedman AS, Segil IM, Lee G, Whitman JF, Nadler LM. B7, a new member of the Ig superfamily with unique expression on activated and neoplastic B cells. J Immunol 1989; 143: 2714-2722.
35. Munro JM, Freedman AS, Aster JC, Gribben JG, Lee NC, Rhynhart KK, Banchereau J, Nadler LM. In vivo expression of the B7 costimulatory molecule by subsets of antigen-presenting cells and the malignant cells of Hodgkin's disease. Blood 1994; 83: 793-798.
36. Valle A, Garrone P, Yssel H, Bonnefoy JY, Freedman AS, Freeman G, Nadler LM, Banchereau J. mAb 104, a new monoclonal antibody, recognizes the B7 antigen that is expressed on activated B cells and HTLV-I-transformed T cells. Immunology 1990; 69: 531-535.
37. Chlichlia K, Moldenhauer G, Daniel PT, Busslinger M, Gazzolo L, Schirrmacher V, Khazaie K. Immediate effects of reversible HTLV-1 tax function: T-cell activation and apoptosis. Oncogene 1995; 10: 269-277.
38. Azuma M, Ito D, Yagita H, Okumura K, Phillips JH, Lanier LL, Somoza C. B70 antigen is a second ligand for CTLA-4 and CD28. Nature 1993; 366: 76-79.
39. Freedman AS. Expression and function of adhesion receptors on normal B cells and B cell non-Hodgkin's lymphomas. Semin Hematol 1993; 30: 318-328.
40. Russell SJ. Lymphokine gene therapy for cancer. Immunol Today 1990; 11: 196-200.
41. Freedman AS, Nadler LM. Cell surface markers in hematologic malignancies. Semin Oncol 1987; 14: 193-212.
42. Griffin JD, Rit J, Nadler LM, Schlossman SF. Expression of myeloid differentiation antigens on normal and malignant myeloid cells. J Clin Invest 1981; 68: 932-941.
43. Freeman GJ, Gribben JG, Boussiotis VA, Ng JW, Restivo VJ, Lombard LA, Gray GS, Nadler LM. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 1993; 262: 909-911.
44. Hathcock KS, Laszlo G, Dickler HB, Bradshaw J, Linsley P, Hodes RJ. Identification of an alternative CTLA-4 ligand costimulatory for T cell activation. Science 1993; 262: 905-907.
45. Freedman AS, Freeman GJ, Rhynhart K, Nadler LM. Selective induction of B7/BB-1 on interferon-gamma stimulated monocytes: a potential mechanism for amplification of T cell activation through the CD28 pathway. Cell Immunol 1991; 137: 429-437.